Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #6896
Reference
MSAN(2020)39
Name
Ranitidine: all formulations: update to MSAN (2019)22 and MSAN (2019)22 first and second updates
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
1. Ranitidine 50mg/2mL injection is anticipated to be unavailable from the end of May 2020 until further notice.
2. Ranitidine film-coated tablets, effervescent tablets and oral solution continue to remain unavailable with no date for resupply.
3. All formulations of ranitidine are affected due to on-going regulatory investigations into the presence of the contaminant, N-nitrosodimethylamine (NDMA), in samples of ranitidine active substance.
4. Clinical advice on alternatives of ranitidine preparations for adults and children has been shared in the previous MSAN (2019)22 second update (see table 1 and 2 in Annex A).
Contact Name
Contact Email
Contact Address
Created
2020-05-07 00:00:00
Click to go back to homepage